Apyx Medical Corp: Form 10-Q for the period ended Jun 30, 2011
Filed with the SEC on Aug 12, 2011 and accepted by EDGAR at Aug 12, 2011, 07:31 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-04-01 to 2011-06-30 | $6.8m | us-gaap:SalesRevenueNet |
| Revenue | 6 months2011-01-01 to 2011-06-30 | $13.0m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2011-04-01 to 2011-06-30 | $3.8m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2011-01-01 to 2011-06-30 | $7.5m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2011-04-01 to 2011-06-30 | $3.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2011-01-01 to 2011-06-30 | $5.5m | us-gaap:GrossProfit |
| Research and development | 3 months2011-04-01 to 2011-06-30 | $289.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2011-01-01 to 2011-06-30 | $635.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2011-04-01 to 2011-06-30 | $1.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2011-01-01 to 2011-06-30 | $2.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2011-04-01 to 2011-06-30 | $549.0k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2011-01-01 to 2011-06-30 | $1.1m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2011-04-01 to 2011-06-30 | −$181.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2011-01-01 to 2011-06-30 | −$364.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2011-04-01 to 2011-06-30 | $429.0k | us-gaap:NetIncomeLoss |
| Net income | 6 months2011-01-01 to 2011-06-30 | $921.0k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2011-04-01 to 2011-06-30 | $0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2011-01-01 to 2011-06-30 | $0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-04-01 to 2011-06-30 | $0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2011-01-01 to 2011-06-30 | $0.05 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2011-01-01 to 2011-06-30 | $2.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2011-01-01 to 2011-06-30 | $261.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-06-30 | $5.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-06-30 | $16.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-06-30 | $28.6m | us-gaap:Assets |
| Current liabilities | At period end2011-06-30 | $2.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-06-30 | $6.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2011-06-30 | $22.6m | us-gaap:StockholdersEquity |
| Shares outstanding | At period end2011-06-30 | 17,742,538 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001140361-11-041343. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.